MAP2K7 and central nervous system cancer: Curiously, we found that the expression of MEK1/2 and ERK1/2 in glioma cells after the treatment of trametinib decreased (Figure 2C), and using the MEK/ERK inhibitor U0126 to block ERK1/2 showed that trametinib can further reduce the expression of PKM2 (Figure 2D).